Sodium zirconium cyclosilicate is a prescription medicine indicated for the treatment of hyperkalemia in adults. It is available as powder for oral suspension. MedsAcross supplies Sodium zirconium cyclosilicate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults.
Source: US FDA prescribing information
LOKELMA (sodium zirconium cyclosilicate) is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. In vitro, LOKELMA has a high affinity for potassium ions, even in the presence of other cations such as calcium and magnesium. LOKELMA increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, thereby lowering serum potassium levels.
Source: US FDA prescribing information
• Recommended starting dose is 10 g administered three times a day for up to 48 hours. • For maintenance treatment, recommended dose is 10 g once daily. Adjust dose at one-week intervals as needed (by 5 g daily) to obtain desired serum potassium target range. Patients on Chronic Hemodialysis • Recommended starting dose is 5 g once daily on non-dialysis days. See full Prescribing Information for additional dosing instructions, as well as reconstitution and administration instructions for the oral suspension.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
• Gastrointestinal Adverse Events in Patients with Motility Disorders. • Edema. • Hypokalemia in patients on hemodialysis. • LOKELMA has radio-opaque properties and, therefore, may give the appearance typical of an imaging agent during abdominal X-ray procedures.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail elsewhere in the label: • Edema. Most common adverse reactions with LOKELMA: mild to moderate edema.
Source: US FDA prescribing information
LOKELMA can transiently increase gastric pH. As a result, LOKELMA can change the absorption of co-administered drugs that exhibit pH-dependent solubility, potentially leading to altered efficacy or safety of these drugs when taken close to the time LOKELMA is administered. In general, other oral medications should be administered at least 2 hours before or 2 hours after LOKELMA. LOKELMA is not expected to impact systemic exposure of drugs that do not exhibit pH-dependent solubility and so spacing is not needed if it has been determined that the concomitant medication does not exhibit pH-dependent solubility. Drug Interactions Thirty-six drugs were tested in-vitro to determine potential interactions with LOKELMA.
Source: US FDA prescribing information
Store LOKELMA at 15°C-30°C (59°F-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Sodium zirconium cyclosilicate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lokelma 10 g/10 g powder for oral suspensionOral | AstraZeneca Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Sodium zirconium cyclosilicate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Sodium zirconium cyclosilicate, including Lokelma.
Yes. The US FDA first approved Sodium zirconium cyclosilicate on 18 May 2018, according to Drugs@FDA.
Yes. Sodium zirconium cyclosilicate has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Sodium zirconium cyclosilicate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Sodium zirconium cyclosilicate is classified under ATC code V03AE10 (Sodium zirconium cyclosilicate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.